Itamidol (Diclofenac)

Diclofenac blocks the cyclooxygenase (COX‑1 and COX‑2) enzymes, which are essential for prostaglandin synthesis. By lowering prostaglandin levels in the treated area, it diminishes inflammation, edema, and the activation of pain receptors, providing localized analgesic and anti‑inflammatory effects.

The appropriate amount of Itamidol is determined by the prescribing healthcare professional based on the specific condition, severity, and patient characteristics. Patients should follow the prescriber’s instructions and the product label for application frequency and quantity.

Safety data for topical diclofenac in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the possible risk, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Itamidol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itamidol delivers diclofenac directly to the skin, offering targeted pain relief with lower systemic exposure compared with oral NSAIDs. This can reduce the risk of gastrointestinal and cardiovascular side effects, although local skin reactions may be more common than with systemic formulations.

Store Itamidol below 25 °C in its original container, protecting it from moisture, heat and direct sunlight. Keep the product out of reach of children and avoid using it after the expiration date printed on the packaging.

Itamidol is applied topically to clean, dry skin. A thin layer is spread over the affected area and gently massaged until absorbed, usually 2–4 times daily or as directed by the prescriber. Occlusive dressings should not be used unless specifically advised.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, systemic NSAID effects like gastrointestinal ulceration, liver toxicity, and renal impairment. Patients should discontinue use and seek medical attention if they experience signs of a severe skin reaction or systemic symptoms.

Itamidol should be avoided in individuals with known hypersensitivity to diclofenac or other NSAIDs, in patients with active skin infections or open wounds at the intended site, and in those with a history of severe cutaneous adverse reactions. Caution is also advised for patients with significant cardiovascular, renal or hepatic disease.